Servier Bio-Innovation LLC

Quick facts

Phase 3 pipeline

• Ivosidenib Oral Tablet · Oncology
  Ivosidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that blocks the production of the oncometabolite 2-hydroxyglutarate, thereby promoting differentiation and apoptosis of IDH1-mutant cancer cells.

Phase 1 pipeline

• S095018
• S095024
• S095024 RDE
• S095029
• S095029 RDE
• S095035

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Servier Bio-Innovation LLC portfolio CI brief
• Servier Bio-Innovation LLC pipeline updates RSS